After the investment, Philip Facchina, chief strategy officer of SurgCenter Development, joined Mesoblast’s board. Mr. Facchina will bring his experience overseeing SurgCenter Development’s strategic relationships in the ASC market to Mesoblast’s board.
“My fellow principals at SurgCenter and I are very excited about the future potential for Mesoblast across the breadth of its platform technology, from chronic heart failure and inflammatory bowel disease to the potential treatment for chronic low back pain,” said Mr. Facchina in a March 29 news release.
Mesoblast develops allogeneic cellular medicines to treat severe inflammatory conditions. It has a proprietary mesenchymal lineage cell therapy technology developed to reduce damaging inflammation.
SurgCenter Development has about 225 orthopedic- and spine-focused ASCs and is partnered with thousands of physicians across the U.S.
More articles on surgery centers:
How shift in thinking, tech investment amid pandemic is paying off for Missouri ASC
How ASC owners can make the most of a sale after pandemic losses
Gloves, gowns and blue sterile wrap: What supplies ASCs are having trouble acquiring
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.